{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:56:14Z","timestamp":1783511774464,"version":"3.55.0"},"reference-count":40,"publisher":"ALUNA","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>The gut microbiota plays an important physiological role in controlling not only the function of the gastrointestinal tract, but also in maintaining systemic homeostasis. Quantitative and \/or qualitative disturbances of the gut microbiota (dysbiosis) are an important element in the complex pathogenesis of many diseases, including chronic kidney disease (CKD). In the disease, the mutual interactions between disturbed gut microbiota and the progression of CKD (pathophysiological \u201ckidney-gut axis\u201d) have been demonstrated. The kidney failure causes water and nitrogen waste retention which leads to disturbances of motility, secretion and absorption in the gastrointestinal tract. These abnormalities contribute to the development of gut dysbiosis, accompanied by overproduction of toxic bacterial metabolites, with their translocation to the peripheral blood and development of endotoxemia. As a consequence, chronic kidney \u201clow-grade\u201d inflammation and oxidative stress develop, with further deterioration of kidney function in the mechanism of the \u201cvicious cycle\u201d of the kidney-gut axis. Considering the key role of gut dysbiosis and the kidney-gut axis, the attempts to restore the gut eubiosis seem to have an important role in the treatment of CKD and may be even regarded as a form of causal therapeutic intervention. The paper briefly discusses the basics of the pathophysiological kidney-gut axis in CKD and potential methods of modulating the abnormal gut microbiota in this disease, including the use of probiotic or prebiotic preparations, agents that absorb bacterial-derived toxins in the intestinal lumen, fecal microbiota transplantation and drugs used so far for other indications (acarbose, meclofenamate, lubiprostone).<\/jats:p>","DOI":"10.36740\/wlek202207127","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T13:13:52Z","timestamp":1660396432000},"page":"1757-1764","source":"Crossref","is-referenced-by-count":7,"title":["POTENTIAL THERAPEUTIC OPTIONS TARGETING THE GUT DYSBIOSIS IN CHRONIC KIDNEY DISEASE"],"prefix":"10.36740","volume":"75","author":[{"given":"\u0141ukasz","family":"Dobrek","sequence":"first","affiliation":[{"name":"DEPARTMENT OF CLINICAL PHARMACOLOGY, WROCLAW MEDICAL UNIVERSITY, WROCLAW, POLAND"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22436","published-online":{"date-parts":[[2022]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Adv Exp Med Biol. 2019;1165:3\u221215.","DOI":"10.1007\/978-981-13-8871-2_1"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322(13):1294\u22121304.","DOI":"10.1001\/jama.2019.14745"},{"key":"ref2","unstructured":"3. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):5\u221214."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int Suppl. 2021;99(3S):S9\u2212S87.","DOI":"10.1016\/j.kint.2020.11.003"},{"key":"ref4","unstructured":"5. Matovinovi\u0107 MS. Pathophysiology and classification of kidney diseases. EJIFCC. 2009;20(1):2\u221211."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Rapa SF, Di Iorio BR, Campiglia P et al. Inflammation and oxidative stress in chronic kidney disease-potential therapeutic role of minerals, vitamins and plant-derived metabolites. Int J Mol Sci. 2019;21(1):263.","DOI":"10.3390\/ijms21010263"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Stavropoulou E, Kantartzi K, Tsigalou C et al. Focus on the gut-kidney axis in health and disease. Front Med (Lausanne). 2021;7:620102.","DOI":"10.3389\/fmed.2020.620102"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Al Khodor S, Shatat IF. Gut microbiome and kidney disease: a bidirectional relationship. Pediatr Nephrol. 2017;32(6):921\u2212931.","DOI":"10.1007\/s00467-016-3392-7"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Shabaka A, Cases-Corona C, Fernandez-Juarez G. Therapeutic insights in chronic kidney disease progression. Front Med (Lausanne). 2021;8:645187.","DOI":"10.3389\/fmed.2021.645187"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Castro MCM. Conservative management for patients with chronic kidney disease refusing dialysis. J Bras Nefrol. 2019;41(1):95\u2212102.","DOI":"10.1590\/2175-8239-jbn-2018-0028"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Jandhyala SM, Talukdar R, Subramanyam C et al. Role of the normal gut microbiota. World J Gastroenterol. 2015;21(29):8787\u2212803.","DOI":"10.3748\/wjg.v21.i29.8787"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. S\u0119dzikowska A, Szablewski L. Human gut microbiota in health and selected cancers. Int J Mol Sci. 2021;22(24):13440.","DOI":"10.3390\/ijms222413440"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Dieterich W, Schink M, Zopf Y. Microbiota in the gastrointestinal tract. Med Sci (Basel). 2018;6(4):116.","DOI":"10.3390\/medsci6040116"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Gomaa EZ. Human gut microbiota\/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 2020;113(12):2019\u22122040.","DOI":"10.1007\/s10482-020-01474-7"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19(1):55\u221271.","DOI":"10.1038\/s41579-020-0433-9"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Cigarran Guldris S, Gonz\u00e1lez Parra E, Cases Amen\u00f3s A. Gut microbiota in chronic kidney disease. Nefrologia. 2017;37(1):9\u221219.","DOI":"10.1016\/j.nefroe.2017.01.017"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Hobby GP, Karaduta O, Dusio GF et al. Chronic kidney disease and the gut microbiome. Am J Physiol Renal Physiol. 2019;316(6):F1211\u2212F1217.","DOI":"10.1152\/ajprenal.00298.2018"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Ren Z, Fan Y, Li A et al. Alterations of the human gut microbiome in chronic kidney disease. Adv Sci (Weinh). 2020;7(20):2001936.","DOI":"10.1002\/advs.202001936"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Chen YY, Chen DQ, Chen L et al. Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease. J Transl Med. 2019;17(1):5.","DOI":"10.1186\/s12967-018-1756-4"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Glorieux G, Gryp T, Perna A. Gut-derived metabolites and their role in immune dysfunction in chronic kidney disease. Toxins (Basel). 2020;12(4):245.","DOI":"10.3390\/toxins12040245"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Rysz J, Franczyk B, \u0141awi\u0144ski J et al. The impact of CKD on uremic toxins and gut microbiota. Toxins (Basel). 2021;13(4):252.","DOI":"10.3390\/toxins13040252"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Snelson M, Biruete A, McFarlane C et al. A renal clinician\u2019s guide to the gut microbiota. J Ren Nutr. 2020;30(5):384\u2212395.","DOI":"10.1053\/j.jrn.2019.11.002"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Kim SM, Song IH. The clinical impact of gut microbiota in chronic kidney disease. Korean J Intern Med. 2020;35:1305\u22121316.","DOI":"10.3904\/kjim.2020.411"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Putri DNA, Nababan CCM. Microbiota-based therapies for chronic kidney disease. Intisari Sains Medis 2019;10(1):57\u221264.","DOI":"10.15562\/ism.v10i1.239"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25. Tsai YL, Lin TL, Chang CJ et al. Probiotics, prebiotics and amelioration of diseases. J Biomed Sci. 2019;26(1):3.","DOI":"10.1186\/s12929-018-0493-6"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Fagundes RAB, Soder TF, Grokoski KC et al. Probiotics in the treatment of chronic kidney disease: a systematic review. J Bras Nefrol. 2018;40(3):278\u2212286.","DOI":"10.1590\/2175-8239-jbn-3931"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Jia L, Jia Q, Yang J et al. Efficacy of probiotics supplementation on chronic kidney disease: a systematic review and meta-analysis. Kidney Blood Press Res. 2018;43(5):1623\u22121635.","DOI":"10.1159\/000494677"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Chen L, Shi J, Ma X et al. Effects of microbiota-driven therapy on circulating indoxyl sulfate and P-cresyl sulfate in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr. 2021. doi: 10.1093\/advances\/nmab149. Epub ahead of print.","DOI":"10.1093\/advances\/nmab149"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. McFarlane C, Ramos CI, Johnson DW et al. Prebiotic, probiotic, and synbiotic supplementation in chronic kidney disease: a Systematic review and meta-analysis. J Ren Nutr. 2019;29(3):209\u2212220.","DOI":"10.1053\/j.jrn.2018.08.008"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30. Chi M, Ma K, Wang J et al. The immunomodulatory effect of the gut microbiota in kidney disease. J Immunol Res. 2021;2021:5516035.","DOI":"10.1155\/2021\/5516035"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Foresto-Neto O, Ghirotto B, C\u00e2mara NOS. Renal sensing of bacterial metabolites in the gut-kidney axis. Kidney360. 2021;2(9):1501\u22121509.","DOI":"10.34067\/kid.0000292021"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32. Locatelli F, Minutolo R. Intestinal adsorption of uremic toxins: a new strategy for anemia management? Nephrol Dial Transplant. 2014;29:1624\u22121627.","DOI":"10.1093\/ndt\/gfu102"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33. Lu PH, Yu MC, Wei MJ et al. The therapeutic strategies for uremic toxins control in chronic kidney disease. Toxins (Basel). 2021;13(8):573.","DOI":"10.3390\/toxins13080573"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Chen YC, Wu MY, Hu PJ et al. Effects and safety of an oral adsorbent on chronic kidney disease progression: a systematic review and meta-analysis. J Clin Med. 2019;8(10):1718.","DOI":"10.3390\/jcm8101718"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. Kee YK, Han SY, Kang DH et al. Comparison of different types of oral adsorbent therapy in patients with chronic kidney disease: a multicenter, randomized, phase IV clinical trial. Yonsei Med J. 2021;62(1):41\u221249.","DOI":"10.3349\/ymj.2021.62.1.41"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. Li Y, Dai M, Yan J et al. Colonic dialysis can influence gut flora to protect renal function in patients with pre dialysis chronic kidney disease. Sci Rep. 2021;11:12773.","DOI":"10.1038\/s41598-021-91722-1"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37. Wang Z, Zhang S, Zheng X et al. Efficacy and safety of colonic dialysis combined with traditional Chinese medicine retention enema in the treatment of chronic renal failure: a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021;100(50):e28082.","DOI":"10.37766\/inplasy2021.10.0116"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. Gupta A, Saha S, Khanna S. Therapies to modulate gut microbiota: past, present and future. World J Gastroenterol. 2020;26(8):777\u2212788.","DOI":"10.3748\/wjg.v26.i8.777"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39. Sharma A, Das P, Buschmann M et al. The future of microbiome-based therapeutics in clinical applications. Clin Pharm Therap. 2020;107:123\u2212128.","DOI":"10.1002\/cpt.1677"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. Barba C, Soulage CO, Caggiano G et al. Effects of fecal microbiota transplantation on composition in mice with CKD. Toxins (Basel). 2020;12(12):741.","DOI":"10.3390\/toxins12120741"}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T13:14:01Z","timestamp":1660396441000},"score":1,"resource":{"primary":{"URL":"https:\/\/wiadlek.pl\/wp-content\/uploads\/archive\/2022\/06\/WLek202207127.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022]]},"published-print":{"date-parts":[[2022,7]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202207127","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"value":"0043-5147","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}